Gene: BCR
Official Full Name: BCR activator of RhoGEF and GTPaseprovided by HGNC
Gene Summary: A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The unregulated tyrosine kinase activity of BCR-ABL1 contributes to the immortality of leukaemic cells. The BCR protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac and other kinases. Two transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2020]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO01965 | BCR Knockout cell line (HeLa) | Human | BCR | 1:3~1:6 | Negative | Online Inquiry |
KO01966 | BCR Knockout cell line (HCT 116) | Human | BCR | 1:2~1:4 | Negative | Online Inquiry |
KO01967 | BCR Knockout cell line (HEK293) | Human | BCR | 1:3~1:6 | Negative | Online Inquiry |
KO01968 | BCR Knockout cell line (A549) | Human | BCR | 1:3~1:4 | Negative | Online Inquiry |
BCR Gene Knockout Cell Lines are genetically engineered cell lines that have had the BCR (Breakpoint Cluster Region) gene specifically inactivated or disrupted. This process typically involves CRISPR/Cas9 technology or RNA interference, enabling researchers to study the functional consequences of the BCR gene loss without the confounding effects of its expression. The knockout of the BCR gene is vital as it plays a significant role in various cellular processes, including signal transduction, hematopoiesis, and tumorigenesis.
The primary function of BCR Gene Knockout Cell Lines is to facilitate the investigation of the BCR gene’s involvement in critical biological pathways and diseases, particularly in cancer research, where its aberration can lead to oncogenic signaling cascades. By using these cell lines, scientists can monitor changes in cell proliferation, differentiation, and apoptosis, thereby elucidating the role of BCR in disease pathogenesis.
From a scientific standpoint, these models are invaluable for understanding the mechanisms behind BCR-related malignancies, such as Chronic Myeloid Leukemia (CML). Their applications extend into therapeutic research—both in the discovery of novel pharmaceuticals and in the development of targeted gene therapies.
What sets BCR Gene Knockout Cell Lines apart from similar products on the market is their high specificity and reliability in replicating in vivo conditions, providing researchers with robust and reproducible data. Additionally, these cell lines are engineered with advanced technologies, ensuring minimal off-target effects, which enhances experimental accuracy.
For researchers and clinicians, these cell lines offer unparalleled opportunities for deepening their understanding of BCR-related diseases, paving the way for novel treatment strategies and innovations. By investing in our BCR Gene Knockout Cell Lines, users gain access to cutting-edge research tools backed by our company’s extensive expertise in genetic engineering and cell biology, positioning them at the forefront of scientific discovery.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.